China Healthwise Holdings Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	7.7yrs

Mises à jour récentes de la gestion

Recent updates

A Look At The Fair Value Of China Healthwise Holdings Limited (HKG:348)

Jul 26

China Healthwise Holdings Limited's (HKG:348) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

May 30

Is China Healthwise Holdings (HKG:348) Using Debt In A Risky Way?

May 21

China Healthwise Holdings Limited's (HKG:348) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors

Mar 28

China Healthwise Holdings (HKG:348) Is Making Moderate Use Of Debt

Dec 11

More Unpleasant Surprises Could Be In Store For China Healthwise Holdings Limited's (HKG:348) Shares After Tumbling 26%

Jun 08

China Healthwise Holdings Limited (HKG:348) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Jun 07

PDG

China Healthwise Holdings n'a pas de PDG, ou nous n'avons pas de données sur eux.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Hong Wai Lei	Executive Chairman	8.1yrs	HK$4.94m	7.35% HK$ 4.8m
Kwok Wai Cheung	Executive Vice Chairman	5.1yrs	HK$4.94m	pas de données
Alex Leung	Executive Director	7.7yrs	HK$3.65m	pas de données
Huixia Yuan	Executive Director	6yrs	HK$1.92m	pas de données
Ming Wan Lo	Company Secretary & Executive Director	7.7yrs	HK$1.09m	pas de données
Hok Lim Lai	Independent Non-Executive Director	8.1yrs	HK$120.00k	pas de données
Wai Hung Lien	Independent Non-Executive Director	8.1yrs	HK$120.00k	pas de données
Chin Pang Tsang	Independent Non-Executive Director	less than a year	pas de données	pas de données

7.7yrs

Durée moyenne de l'emploi

50.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 348 sont considérés comme expérimentés (ancienneté moyenne 7.7 ans).

China Healthwise Holdings Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

China Healthwise Holdings Limited, Annual General Meeting, Jun 18, 2024

Less than half of directors are independent

Executive Chairman recently sold HK$208k worth of stock

Less than half of directors are independent

Recent updates

First half 2024 earnings released: HK$0.037 loss per share (vs HK$0.041 loss in 1H 2023)

China Healthwise Holdings Limited announced that it expects to receive HKD 16.8 million in funding from Heng Tai Finance Limited

China Healthwise Holdings Limited to Report First Half, 2024 Results on Aug 26, 2024

A Look At The Fair Value Of China Healthwise Holdings Limited (HKG:348)

Now 21% undervalued after recent price drop

China Healthwise Holdings Limited's (HKG:348) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Is China Healthwise Holdings (HKG:348) Using Debt In A Risky Way?

China Healthwise Holdings Limited, Annual General Meeting, Jun 18, 2024

China Healthwise Holdings Limited's (HKG:348) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.07 loss in FY 2022)

China Healthwise Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

China Healthwise Holdings (HKG:348) Is Making Moderate Use Of Debt

New major risk - Share price stability

First half 2023 earnings released: HK$0.041 loss per share (vs HK$0.02 loss in 1H 2022)

China Healthwise Holdings Limited to Report First Half, 2023 Results on Aug 24, 2023

New major risk - Market cap size

More Unpleasant Surprises Could Be In Store For China Healthwise Holdings Limited's (HKG:348) Shares After Tumbling 26%

China Healthwise Holdings Limited (HKG:348) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Does China Healthwise Holdings (HKG:348) Have A Healthy Balance Sheet?

Full year 2022 earnings released: HK$0.07 loss per share (vs HK$0.13 loss in FY 2021)

Less than half of directors are independent

China Healthwise Holdings (HKG:348) Is Carrying A Fair Bit Of Debt

First half 2022 earnings released: HK$0.02 loss per share (vs HK$0.047 profit in 1H 2021)

China Healthwise Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

China Healthwise Holdings Limited Announces Earnings Guidance for the Half Year 2022

China Healthwise Holdings Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2022

Executive Chairman recently sold HK$208k worth of stock

Less than half of directors are independent

Full year 2021 earnings released: HK$0.13 loss per share (vs HK$0.089 loss in FY 2020)

Is China Healthwise Holdings (HKG:348) Using Too Much Debt?

China Healthwise Holdings (HKG:348) Has Debt But No Earnings; Should You Worry?

China Healthwise Holdings Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: HK$0.21

New 90-day low: HK$0.23

New 90-day low: HK$0.24

Ngai Ling entered into the sale and purchase agreement to acquire Kid Galaxy Corporation from China Healthwise Holdings Limited (SEHK:348) for HKD 8.6 million.

China Healthwise Holdings Limited to Report First Half, 2020 Results on Aug 21, 2020

PDG

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen